Susquehanna International Group
SRPT icon

Susquehanna International Group’s Sarepta Therapeutics SRPT Stock Holding History

Susquehanna International Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.7M Buy
1,640,600
+193,400
+13% +$3.74M ﹤0.01% 1565
2025
Q4 		$31.1M Buy
1,447,200
+55,700
+4% +$1.17M ﹤0.01% 1785
2025
Q3 		$26.8M Sell
1,391,500
-52,200
-4% -$931K ﹤0.01% 1896
2025
Q2 		$24.7M Buy
1,443,700
+987,100
+216% +$42.1M ﹤0.01% 1794
2025
Q1 		$29.1M Sell
456,600
-11,300
-2% -$1.19M 0.01% 1411
2024
Q4 		$56.9M Buy
467,900
+31,300
+7% +$3.84M 0.01% 1015
2024
Q3 		$54.5M Sell
436,600
-164,600
-27% -$22.8M 0.01% 1020
2024
Q2 		$95M Sell
601,200
-111,400
-16% -$14.3M 0.02% 628
2024
Q1 		$92.3M Sell
712,600
-188,200
-21% -$23.1M 0.02% 715
2023
Q4 		$86.9M Buy
900,800
+376,500
+72% +$36.1M 0.02% 737
2023
Q3 		$63.6M Sell
524,300
-17,300
-3% -$1.96M 0.01% 857
2023
Q2 		$62M Buy
541,600
+25,000
+5% +$3.22M 0.01% 854
2023
Q1 		$71.2M Buy
516,600
+145,600
+39% +$18.9M 0.02% 755
2022
Q4 		$48.1M Buy
371,000
+33,200
+10% +$3.85M 0.01% 905
2022
Q3 		$37.3M Sell
337,800
-6,900
-2% -$695K 0.01% 979
2022
Q2 		$25.8M Sell
344,700
-59,200
-15% -$4.36M 0.01% 1254
2022
Q1 		$31.6M Buy
403,900
+93,200
+30% +$7.14M 0.01% 1311
2021
Q4 		$28M Buy
310,700
+24,100
+8% +$2.06M ﹤0.01% 1533
2021
Q3 		$26.5M Sell
286,600
-60,200
-17% -$4.64M ﹤0.01% 1700
2021
Q2 		$27M Buy
346,800
+48,300
+16% +$3.66M ﹤0.01% 1713
2021
Q1 		$22.2M Sell
298,500
-310,200
-51% -$28.6M ﹤0.01% 1755
2020
Q4 		$104M Sell
608,700
-42,800
-7% -$6.34M 0.02% 644
2020
Q3 		$91.5M Sell
651,500
-43,600
-6% -$6.63M 0.02% 606
2020
Q2 		$111M Buy
695,100
+386,300
+125% +$52.6M 0.03% 466
2020
Q1 		$30.2M Sell
308,800
-1,059,600
-77% -$121M 0.01% 932
2019
Q4 		$177M Buy
1,368,400
+332,400
+32% +$33.5M 0.05% 308
2019
Q3 		$78M Buy
1,036,000
+86,700
+9% +$10.2M 0.03% 540
2019
Q2 		$144M Buy
949,300
+68,200
+8% +$8.29M 0.05% 309
2019
Q1 		$105M Buy
881,100
+303,100
+52% +$39M 0.04% 361
2018
Q4 		$63.1M Sell
578,000
-443,800
-43% -$55.5M 0.03% 520
2018
Q3 		$165M Buy
1,021,800
+57,100
+6% +$7.81M 0.05% 290
2018
Q2 		$128M Buy
964,700
+100,400
+12% +$9.47M 0.04% 342
2018
Q1 		$64M Sell
864,300
-1,155,400
-57% -$77M 0.02% 562
2017
Q4 		$112M Buy
2,019,700
+884,900
+78% +$46.9M 0.04% 384
2017
Q3 		$51.5M Sell
1,134,800
-83,200
-7% -$3.33M 0.02% 630
2017
Q2 		$41.1M Buy
1,218,000
+392,800
+48% +$12.8M 0.02% 707
2017
Q1 		$24.4M Sell
825,200
-217,800
-21% -$6.74M 0.01% 940
2016
Q4 		$28.6M Sell
1,043,000
-592,800
-36% -$23.8M 0.01% 819
2016
Q3 		$100M Sell
1,635,800
-339,100
-17% -$10.3M 0.05% 318
2016
Q2 		$37.7M Buy
1,974,900
+397,000
+25% +$7.35M 0.02% 621
2016
Q1 		$30.8M Buy
1,577,900
+458,400
+41% +$8.01M 0.02% 737
2015
Q4 		$43.2M Buy
1,119,500
+494,500
+79% +$16M 0.02% 673
2015
Q3 		$20.1M Sell
625,000
-167,600
-21% -$5.69M 0.01% 1204
2015
Q2 		$24.1M Buy
792,600
+232,200
+41% +$4.75M 0.01% 1141
2015
Q1 		$7.44M Sell
560,400
-697,100
-55% -$9.29M ﹤0.01% 2210
2014
Q4 		$18.2M Buy
1,257,500
+381,900
+44% +$6.47M 0.01% 1430
2014
Q3 		$18.5M Sell
875,600
-39,500
-4% -$891K 0.01% 1496
2014
Q2 		$27.3M Sell
915,100
-862,400
-49% -$27.3M 0.01% 1124
2014
Q1 		$42.7M Buy
1,777,500
+247,100
+16% +$6.3M 0.02% 720
2013
Q4 		$31.2M Sell
1,530,400
-364,200
-19% -$10.8M 0.01% 963
2013
Q3 		$89.5M Buy
1,894,600
+577,000
+44% +$22.2M 0.05% 343
2013
Q2 		$50.1M Buy
+1,317,600
New +$47.1M 0.03% 552

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's SRPT Position: Q1 2026 in Review

Susquehanna International Group increased its Sarepta Therapeutics (SRPT) stake by 110% in Q1 2026, buying an estimated $9.1M and bringing the position to 897,532 shares worth $19.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2253.

Susquehanna International Group first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $124M in Q2 2018. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Susquehanna International Group held 897,532 shares of Sarepta Therapeutics worth $19.5M as of Q1 2026.
  • Susquehanna International Group bought 469,923 Sarepta Therapeutics shares in Q1 2026, an estimated $9.1M.
  • Sarepta Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2253 holding.
  • Susquehanna International Group first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Susquehanna International Group's Sarepta Therapeutics position peaked at $124M in Q2 2018.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.